Gujarat Inject (Kerala) Share Price & Earnings Call Analysis

₹10.86-2.51% today

Market cap: ₹159 Cr
P/E: 53.02
ROE: 16.58%
PEG: 0.21
Price to sales: 3.40
Debt to equity: 0.00
52W high / low: ₹133 / ₹9.08
Sales growth (5Y): 415.26%
EBITDA margin: 8.41%
Net profit margin: 4.98%
Sales (last year): ₹46 Cr

All 11 ratios ↓

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

See all potential multibaggers Where does Gujarat Inject (Kerala) rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

1. Pick 3–15 stocks
2. Choose large, mid or small cap and your sectors
3. Get a portfolio built from the rankings

Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#	Company	Revenue guided	Margin guided	Market cap	P/E
1		40%+	Up 2%+	₹480 Cr	19.1
2		40%+	Up 0–2%	₹212 Cr	16.1
3		40%+	Flat	₹17,925 Cr	—
4		40%+	Flat	₹4,268 Cr	—
5		40%+	Flat	₹40 Cr	—
6		20–40%	Up 2%+	₹51,093 Cr	44.6

Sign up free to see every company in the sector ranking and track Gujarat Inject (Kerala).

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Gujarat Inject (Kerala) announcements

All announcements →

Fundraise / allotmentMajor development5 Nov 2026
Gujarat Inject (Kerala) approves Q2 and H1 standalone results to 30 Sep 2026

Financials of Gujarat Inject (Kerala)

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Gujarat Inject (Kerala)

Quarterly Results

Quarter-by-quarter operating performance

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales +	0.00	0.15	0.00	0.22	5.42	3.05	8.61	3.15	4.24	2.42	1.58	1.63	30.70
Expenses +	0.02	0.11	0.00	0.25	5.37	2.88	8.07	2.87	4.15	2.32	1.55	1.72	28.43
Operating Profit	-0.02	0.04	0.00	-0.03	0.05	0.17	0.54	0.28	0.09	0.10	0.03	-0.09	2.27
OPM %		26.67%		-13.64%	0.92%	5.57%	6.27%	8.89%	2.12%	4.13%	1.90%	-5.52%	7.39%
Other Income +	0.03	0.00	0.02	0.04	0.00	0.00	0.17	0.00	0.01	0.00	0.06	0.14	0.00
Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Profit before tax	0.01	0.04	0.02	0.01	0.05	0.17	0.71	0.28	0.10	0.10	0.09	0.05	2.27
Tax %	0.00%	25.00%	0.00%	0.00%	20.00%	23.53%	14.08%	25.00%	30.00%	20.00%	22.22%	20.00%	27.75%
Net Profit +	0.01	0.03	0.01	0.00	0.04	0.12	0.61	0.21	0.07	0.07	0.07	0.04	1.64
EPS in Rs	0.02	0.06	0.02	0.00	0.04	0.08	0.42	0.14	0.05	0.05	0.05	0.03	1.12

Financials of Gujarat Inject (Kerala)

Profit & Loss

Annual income statement trend

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Sales +	0.00	0.02	1.57	0.00	0.00	0.00	0.01	0.02	0.17	5.79	19.05	36.32
Expenses +	0.00	0.02	1.56	0.07	0.03	0.01	0.13	0.07	0.54	5.74	17.98	34.02
Operating Profit	0.00	0.00	0.01	-0.07	-0.03	-0.01	-0.12	-0.05	-0.37	0.05	1.07	2.30
OPM %		0.00%	0.64%				-1,200.00%	-250.00%	-217.65%	0.86%	5.62%	6.33%
Other Income +	0.00	2.30	0.00	0.05	0.02	0.01	0.01	0.05	0.43	0.06	0.18	0.20
Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Profit before tax	0.00	2.30	0.01	-0.02	-0.01	0.00	-0.11	0.00	0.06	0.11	1.25	2.50
Tax %		0.00%	0.00%	0.00%	0.00%		0.00%		16.67%	18.18%	19.20%	27.60%
Net Profit +	0.00	2.30	0.01	-0.02	-0.01	0.00	-0.11	0.00	0.04	0.08	1.02	1.81
EPS in Rs	0.00	4.69	0.02	-0.04	-0.02	0.00	-0.22	0.00	0.08	0.07	0.70	1.24
Dividend Payout %		0.00%	0.00%	0.00%	0.00%		0.00%		0.00%	0.00%	0.00%	0.00%

Financials of Gujarat Inject (Kerala)

Balance Sheet

Capital structure and asset base

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	4.88	4.88	4.88	4.88	4.88	4.88	4.88	4.88	4.88	11.29	14.63	14.63
Reserves	-7.95	-5.64	-5.64	-5.66	-5.66	-5.66	-5.77	-5.76	-5.72	-2.75	-4.62	-2.81
Borrowings +	2.86	0.56	0.57	0.59	0.59	0.59	0.69	0.73	0.61	0.00	0.00	0.00
Other Liabilities +	0.38	0.36	0.20	0.21	0.20	0.20	0.22	0.22	0.53	0.15	1.94	24.85
Total Liabilities	0.17	0.16	0.01	0.02	0.01	0.01	0.02	0.07	0.30	8.69	11.95	36.67
Fixed Assets +	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	20.76
CWIP	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets +	0.17	0.16	0.01	0.02	0.01	0.01	0.02	0.07	0.30	8.69	11.95	15.91
Total Assets	0.17	0.16	0.01	0.02	0.01	0.01	0.02	0.07	0.30	8.69	11.95	36.67

Financials of Gujarat Inject (Kerala)

Cash Flows

Operating, investing and financing cash movement

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity +	0.00	0.00	0.00	-0.01	0.00	0.00	-0.11	0.00	0.05	-6.03	-1.55	21.22
Cash from Investing Activity +	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.18	-20.57
Cash from Financing Activity +	0.00	0.00	0.00	0.00	0.00	0.00	0.10	0.00	0.00	8.88	-1.53	0.00
Net Cash Flow	0.00	0.00	0.00	-0.01	0.00	0.00	0.00	0.00	0.05	2.86	-2.89	0.65
Free Cash Flow	0.00	0.00	0.00	-0.01	0.00	0.00	-0.11	0.00	0.05	-6.03	-1.55	0.46
CFO/OP			0%	14%	0%	0%	92%	0%	-16%	-12,020%	-122%	953%

Financials of Gujarat Inject (Kerala)

Ratios

Working capital efficiency and return ratios

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days		0.00	0.00				0.00	0.00	0.00	187.86	137.57	63.81
Inventory Days			0.00				0.00	0.00	0.00	0.00	0.00	0.00
Days Payable
Cash Conversion Cycle		0.00	0.00				0.00	0.00	0.00	187.86	137.57	63.81
Working Capital Days		-8,395.00	-106.94				-17,520.00	-9,490.00	-1,545.88	354.91	153.47	-140.29
ROCE %										2.65%	13.48%	22.89%

Others in Pharmaceuticals & Biotechnology this season

Symbiotec Pharma (Q2 FY27)
280 Cr, up 43% YoY from Rs. Key investor presentation takeaways from Symbiotec Pharmalab Ltd's Q2 FY27 investor presentation — and how it ranks against sector p
Hester Bios (Q2 FY27)
Standalone Q2 FY27 revenue: INR 829.28 million, up 28% YoY (from INR 645.79 million in Q2 FY26). Key results statement takeaways from Hester Biosciences Ltd's Q
Glenmark Pharmaceuticals (Q2 FY27)
42,473 million, down 29.8% YoY. Key investor presentation takeaways from Glenmark Pharmaceuticals Ltd's Q2 FY27 investor presentation — and how it ranks against
Windlas Biotech (Q2 FY27)
264 Cr, a 19% YoY increase from Rs. Key investor presentation takeaways from Windlas Biotech Ltd's Q2 FY27 investor presentation — and how it ranks against sect

Compare:vs Sun Pharmaceutical Industries vs Divis Laboratories vs Torrent Pharmaceuticals